Key Takeaways
- Cellyan Biotechnology receives an additional 180 days from Nasdaq to comply with the $1.00 bid price requirement.
- The company’s shares closed at $0.43, down 5.18%, and dropped to $0.34 in after-hours trading.
- Cellyan may consider a reverse stock split to regain compliance if necessary.
Compliance Extension from Nasdaq
Cellyan Biotechnology Co. Ltd (NASDAQ:HKPD) is facing challenges in maintaining its stock price, prompting Nasdaq to grant the company an additional 180-day compliance period. This extension allows Cellyan until January 11, 2027, to meet the minimum closing bid price requirement of $1.00. Currently, HKPD shares ended the regular trading day at $0.43, marking a decline of 5.18%. In after-hours trading, the stock experienced a further drop, falling to $0.34, representing a total decline of 20.79%.
The company specializes in over-the-counter pharmaceutical cross-border e-commerce supply chain and procurement services through its Hong Kong subsidiaries. To restore compliance with Nasdaq’s listing standards, Cellyan must achieve a closing bid price of at least $1.00 for a minimum of 10 consecutive business days before the extension deadline. While Cellyan indicated its intention to pursue all feasible measures to regain compliance, it also acknowledged there is no guarantee the listing requirement will be satisfied within the designated timeframe.
Apart from the bid price issue, Nasdaq confirmed that Cellyan meets all other initial listing standards for the Nasdaq Capital Market. As a potential strategy, the company mentioned it might consider a reverse stock split should compliance efforts falter. Notably, this compliance notification does not impact the ongoing trading of HKPD shares, which will continue to be available on the Nasdaq Capital Market.
From a trading perspective, Cellyan’s market capitalization stands at approximately $10.2 million. The stock’s performance has been markedly poor over the past year, with a substantial 69.03% decline. The company has experienced a 52-week high of $2.58 and a low of $0.32. Current trends indicate a persistent decline across short-, medium-, and long-term horizons, as noted by the Benzinga Edge Stock Rankings.
As of now, Cellyan Biotechnology must navigate these challenges as it works to bolster its stock price and secure its position on the Nasdaq exchange.
The content above is a summary. For more details, see the source article.